Estimating Benefit in Ambulatory Heart Failure Patients MedaMACS Progress Report 2014 Garrick C. Stewart, MD Brigham and Women’s Hospital.

Slides:



Advertisements
Similar presentations
Presented By : Mahgul Gulzai ( ).  Introduction  History  Types of Artificial Heart  Why do we need Artificial Heart  Artificial Heart Surgery.
Advertisements

THE PATIENT’S JOURNEY TO TRANSPLANT AND BEYOND
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Can Comparative Effectiveness Study Tell Us What Is The Best Therapy For Class IV Heart Failure? Beta blockers or LVADs?
The Key to Success: INTERMACS Hospitals Site Utilization of INTERMACS Data and Reports for local QI Quality Assurance and data quality Evaluation of Site.
Monica Colvin-Adams, MD Assistant Professor of Medicine Advanced Heart Failure and Transplantation University of Minnesota Compassionate Allowances Outreach.
Disability, Frailty and Co-morbidity Gero 302 Jan 2012.
Organ Donation & Transplantation in Ireland – Changing times Aileen Counihan Transplant Co-ordinator Beaumont Hospital Beaumont Hospital.
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Use of Psoas Muscle Size as a Frailty Assessment Tool for Open and Transcatheter Aortic Valve Replacement Raghavendra Paknikar BS Jeffrey Friedman BS David.
Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,
Between May 2013 and June 2014, we implanted the C-Pulse device in 7 male and 1 female patients with a mean age ± SD of 61.1 ± 9.4 years. Four had ischemic.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
Readmission and Chronic illness that could benefit from end of life discussions.
Patient-Physician Partnership to Improve HBP Adherence Lisa A. Cooper, MD, MPH Associate Professor of Medicine, Epidemiology, and Health Behavior & Society.
Epidemiology of Stroke Dexter L. Morris, PhD, MD Department of Emergency Medicine University of North Carolina School of Medicine Chapel Hill, NC.
Lookback Module: What you should know 2012 National Conference on Health Statistics Monitoring Health Care Reform through Provider-based Surveys: New Initiatives.
Joseph G. Rogers, MD Professor of Medicine Duke University
Coordinator Training Session: March 11, 2012 Major Changes in Data EntryMyers 1 What is the same? What is reduced/removed? What is added/expanded? INTERMACS.
Emily O’Brien, Emil Fosbol, Andrew Peng, Karen Alexander, Matthew Roe, Eric Peterson The Obesity Paradox: The Importance for Long-term Outcomes in Non-ST-Elevation.
The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.
An International Case Study of Lung Transplantation
Keith Aaronson, Mark Slaughter, Edwin McGee, William Cotts, Michael Acker, Mariell Jessup, Igor Gregoric, Pranav Loyalka, Valluvan Jeevanandam, Allen Anderson,
Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Epidemiology of CVD in the Elderly Karen P. Alexander MD Duke University Medical Center Duke Clinical Research Institute Disclosures: (1) Minor Research:
® From Bad to Worse: Comorbidities and Chronic Lower Back Pain Margaret Cecere JD, Richard Young MD, Sandra Burge PhD The University of Texas Health Science.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.
HeartWare HVAD: Risk Factors for Adverse Outcomes Mark S. Slaughter, MD Professor and Chair Department Cardiovascular and Thoracic Surgery University of.
Thomas S. Rector, PhD, Inder S. Anand, MD, David Nelson, PhD, Kristine Ensrud, MD and Ann Bangerter, MS CHF QUERI NETWORK November 8, 2007 VA Medical Center,
Background  Obesity is an extremely common problem ~ 1/3 of adult Americans are obese  Patients commonly ask physicians for advice on weight loss, yet.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for Health Statistics 1 Monitoring Million Hearts.
Red Cell Distribution Width (RDW) as a Novel Prognostic Marker in Heart Failure: Data from the CHARM Program and the Duke Databank.
New Technologies & Challenges in optimizing the “heart health” of Australia Professor Simon Stewart Head, Preventative Cardiology
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical.
Elizabeth Ofili, M.D., M.P.H., F.A.C.C. Professor of Medicine and Chief of Cardiology Director, Clinical Research Center Associate Dean of Clinical Research.
RISK STRATIFICATION. Established by the CACR in Sept National Guidelines Committee The committee acknowledged the support of the Canadian Cardiovascular.
Internet-based Telemedicine for Cardiovascular Disease Management Alfred A. Bove, MD, PhD Cardiology Section Temple University Medical Center.
Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.
Advanced Therapies Lee R. Goldberg, MD, MPH Medical Director, Heart Failure and Cardiac Transplant Program University of Pennsylvania.
Mechanical Circulatory Support in Special Populations Renzo Y. Loyaga-Rendon MD.,PhD.. Assistant Professor Advanced Heart Failure Section University of.
Routine Preventive Care and Cancer Surveillance in Long-Term Survivors (LTS) of Colorectal Cancer: Results from NSABP Protocol LTS-01 Hiroko Kunitake MD.
Embargoed Until 3:45 p.m. ET, Sunday, Nov. 8, 2015
Copenhagen University Hospital Rigshospitalet, Denmark
Embargoed Until 3:45 p.m. ET, Sunday, Nov. 8, 2015
Analysis of Pump Thrombosis in the Intermacs Database Michael Acker William Measey Professor of Surgery Chief of Division of Cardiovascular Surgery Director.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC Yazid NJ Al Hamarneh, BPharm, PhD Charlotte Jones, MD, PhD, FRCP(C) Brenda Hemmelgarn, MD, PhD, FRCP(C)
Eric J Robinson, M.D. Cardiologist April 25, 2015
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Chronic Haemodialysis therapy in octogenarians with ESRF: demographics and outcomes from a single centre in England Dr Punit Yadav Dr Jyoti Baharani.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Joseph J.Y. Sung, MD et al. Am J Gastroenterol 2010;105. R3 김민경.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Brighton and Hove PPMA Preventing Premature Mortality Audit Dr James Simpkin Clinical Facilitator BHPPMA
Pharmacy in Public Health: Describing Populations Course, date, etc. info.
Adult Palliative Care in a Value Based Payment Model
HOPE: Heart Outcomes Prevention Evaluation study
Intermacs and the Scientific Registry of Transplant Recipients (SRTR)
More Than Survival: Futility
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Physical Activity and Endometrial Cancer Survival
Impact of Marital Status on LVAD Mortality: A Single Center Experience Linda Njoroge MD, Mohamed Khayata MD, Kevin Charnas, Paul Bate, Madison Edge, James.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Alignment of Comparative Effectiveness through MedaMACS
Presentation transcript:

Estimating Benefit in Ambulatory Heart Failure Patients MedaMACS Progress Report 2014 Garrick C. Stewart, MD Brigham and Women’s Hospital

Disclosures Consulting for Thoratec Corporation

Enrollment Progress through 5/1/ Centersn=83

Baseline Demographics & Clinical Features Baseline Demographics & Clinical Features n=74 Variable Mean(SD) or % Age, yrs58 (11) Female34 White66 Hispanic9 Working19 Disability52 Data through 4/1/2014 Variable Mean(SD) or % INTERMACS Profile Ejection Fraction, %21 (7)

Clinical Enrollment Data Clinical Enrollment Data n=74 Variable% Outpatient status63 Followed >1 yr by center62 Cardiac Hosp prior 12mos ≥333 Prior Transplant eval26 Prior DT VAD eval12 Ischemic Etiology31 Prior Cardiac Surgery24 Data through 4/1/2014

Burden of Comorbid Conditions Burden of Comorbid Conditions n=74 Variable% Diabetes41 Chronic kidney disease37 Pulmonary hypertension34 Chronic lung disease28 Morbid obesity34 Prior stroke8 History of cancer11 Limited social support18 Repeated non-compliance19 History of smoking37 Data through 4/1/2014

MedaMACS Study Encounters Inpt or outpt 1 Month Re-Look Baseline 6 mos Phone Interview 1 Yr Face-to-face 18m 2 Yrs Phone Interview outpt AB C Time Zero D Telephone Contact Study Site Phone Calls 6 and 18 mos Events (hosp, stroke, transplant, vad, inotropes, death) Meds, Euroqol, NYHA/INTERMACS profile One month End 6MW Gait speed Euroqol+KCCQ VAD Survey Events Risk Scores Treatments Baseline B 6MW Gait speed Euroqol+KCCQ VAD Survey Risk Scores 6MW Gait speed Euroqol+KCCQ VAD Survey Events Treatments Baseline A 6MW Gait speed Euroqol+KCCQ VAD Survey Events Risk Scores Treatments Consent 1mo. 12mos 24mos Face-to-face encounters 1-Yr Visit C 2-Yr Visit D

Early Reassessment Uncovers Divergent Patient Trajectories % Δ5 points in EuroQOL VAS Functional Capacity Quality of Life n=37n=53

Patient Feelings About Receiving a VAD % Change From A  B Toward VAD 32% No Change 49% Away from VAD 19% n=53 with paired data

Physician Estimates of Need for Stage D Intervention in Next Year % Change From A  B More likely 20% No Change 51% Less likely 29% n=53 with paired data

Patient Centered Outcomes Beyond Survival MedaMACSINTERMACS Events/HospitalizationsStroke, GI bleeding, infection, transplant, worsening heart failure Metabolic ProfileNutrition, renal function, BMI Functional Capacity6 minute walk FrailtyGait speed Quality of LifeEuroQOL-5D, KCCQ, Stress/Coping/Satisfaction Survey

Early Outcomes and Events 52 hospitalizations 7 deaths 1 transplant 3 VADs 1 consent withdrawn 83 Baseline A 64 Baseline B 14 6mos f/u Story of the Three VADs… All men, 2 working full time at enrollment, all three obese, two with pulmonary hypertension, ALL in INTERMACS profiles 6/7 at Baseline A

Linking MedaMACS to INTERMACS Medical Therapy Mechanical Support

MedaMACS: The Road Ahead Patient-centered outcomes beyond survival are required in the “less sick” Map journey in parallel and in series with MCS Explore triage points for MCS –Frailty, patient willingness, QOL Forum for hypothesis-driven research in ambulatory advanced HF population Inform the conversation with our HF patients

Acknowledgements MedaMACS investigators and coordinators UAB team at the DCC Ryan Cantor